PCVX (Vaxcyte, Inc.) Stock Financials & Earnings | Market Cap Arena

PCVX (Vaxcyte, Inc.) Stock Financials & Earnings | Market Cap Arena

PCVXVaxcyte, Inc.

Mkt Cap$9B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$767M

EPS (TTM)-$5.63

Free Cash Flow (TTM)-$669M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$71M
Q2 23	$0	$0	-$87M
Q3 23	$0	$0	-$113M
Q4 23	$0	$0	-$197M
Q1 24	$0	$0	-$114M
Q2 24	$0	$0	-$153M
Q3 24	$0	$0	-$140M
Q4 24	$0	$0	-$162M
Q1 25	$0	$0	-$181M
Q2 25	$0	-$5M	-$226M
Q3 25	$0	$0	-$242M
Q4 25	$0	$5M	-$274M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$48M	-$53M
Q2 23	-$63M	-$61M
Q3 23	-$58M	-$65M
Q4 23	-$129M	-$186M
Q1 24	-$159M	-$171M
Q2 24	-$121M	-$167M
Q3 24	-$61M	-$99M
Q4 24	-$111M	-$141M
Q1 25	-$166M	-$193M
Q2 25	-$121M	-$102M
Q3 25	-$143M	-$155M
Q4 25	-$225M	-$219M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$6M
Q2 23	$2M
Q3 23	$7M
Q4 23	$57M
Q1 24	$12M
Q2 24	$45M
Q3 24	$38M
Q4 24	$30M
Q1 25	$27M
Q2 25	$20M
Q3 25	$12M
Q4 25	$6M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+81.5%
Q2 23	—	+82.0%
Q3 23	—	+93.0%
Q4 23	—	+127.2%
Q1 24	—	+60.8%
Q2 24	—	+75.5%
Q3 24	—	+23.8%
Q4 24	—	-17.5%
Q1 25	—	+57.9%
Q2 25	—	+47.9%
Q3 25	—	+73.2%
Q4 25	—	+69.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$10M	—
Q2 23	$13M	—
Q3 23	$13M	—
Q4 23	$13M	—
Q1 24	$18M	—
Q2 24	$22M	—
Q3 24	$21M	—
Q4 24	$24M	—
Q1 25	$31M	—
Q2 25	$37M	—
Q3 25	$35M	—
Q4 25	$36M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$58M	$13M
Q2 23	$73M	$14M
Q3 23	$97M	$16M
Q4 23	$104M	$18M
Q1 24	$95M	$20M
Q2 24	$132M	$21M
Q3 24	$117M	$23M
Q4 24	$134M	$29M
Q1 25	$148M	$33M
Q2 25	$194M	$32M
Q3 25	$210M	$32M
Q4 25	$242M	$32M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$380M	$442M	$822M
Q2 23	$531M	$756M	$1.3B
Q3 23	$545M	$721M	$1.3B
Q4 23	$397M	$683M	$1.1B
Q1 24	$612M	$875M	$1.5B
Q2 24	$519M	$934M	$1.5B
Q3 24	$1.1B	$1.1B	$2.2B
Q4 24	$388M	$1.4B	$1.7B
Q1 25	$347M	$1.3B	$1.7B
Q2 25	$307M	$1.4B	$1.7B
Q3 25	$281M	$1.4B	$1.7B
Q4 25	$174M	$1.4B	$1.6B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	86M	+14.1%
Q2 23	98M	+13.7%
Q3 23	102M	+3.7%
Q4 23	104M	+2.7%
Q1 24	112M	+7.0%
Q2 24	117M	+5.0%
Q3 24	124M	+5.5%
Q4 24	123M	-0.7%
Q1 25	136M	+10.5%
Q2 25	136M	+0.3%
Q3 25	136M	+0.1%
Q4 25	136M	-0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 17	—	—
FY 18	—	—
FY 19	—	—
FY 20	$0	58
FY 21	$0	89
FY 22	$0	158
FY 23	$0	254
FY 24	$0	414
FY 25	$0	507